v3.26.1
Document and Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2025
Mar. 01, 2026
Jun. 30, 2025
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2025    
Document Fiscal Year Focus 2025    
Document Fiscal Period Focus FY    
Entity File Number 001-41947    
Entity Registrant Name Kyverna Therapeutics, Inc.    
Entity Central Index Key 0001994702    
Current Fiscal Year End Date --12-31    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 83-1365441    
Entity Address, Address Line One 5980 Horton St.    
Entity Address, Address Line Two STE 550    
Entity Address, City or Town Emeryville    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 94608    
City Area Code (510)    
Local Phone Number 925-2492    
Title of 12(b) Security Common Stock, par value $0.00001 per share    
Trading Symbol KYTX    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Entity Ex Transition Period false    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Document Annual Report true    
Document Transition Report false    
Entity Public Float     $ 64.5
Entity Common Stock, Shares Outstanding   60,439,893  
Documents Incorporated by Reference [Text Block]

DOCUMENTS INCORPORATED BY REFERENCE

None.

    
Auditor Firm ID 243    
Auditor Location San Diego, California    
Auditor Name BDO USA, P.C.    
Auditor Opinion [Text Block]

Opinion on the Financial Statements

We have audited the accompanying balance sheets of Kyverna Therapeutics, Inc. (the “Company”) as of December 31, 2025 and 2024, the related statements of operations and comprehensive loss, redeemable convertible preferred stock and stockholders’ equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.